Key Facts
• August 20, 2025: Novo Nordisk announces global hiring freeze for non-essential roles.
• Obesity drug Wegovy drives growth but faces competition from Eli Lilly.
• CEO change: Lars Fruergaard Jørgensen replaced by Marcus Schindler in late July.
• New CEO Marcus Schindler explores cost-cutting measures, including potential layoffs.
• Company revised earnings forecast downward in late July 2025.
Summary
Novo Nordisk, a leading Danish pharmaceutical company, has implemented a global hiring freeze for non-essential roles as of August 20, 2025. Despite strong sales of its obesity drug Wegovy, the company faces increasing competition from rivals like Eli Lilly. In late July, Novo Nordisk revised its earnings forecast downward and announced a leadership change, appointing Marcus Schindler as the new CEO. Schindler, on his first day as CEO, indicated plans to explore cost-cutting measures, including potential layoffs, to navigate the challenging market environment.
